and Schisandra sphenanthera Rehd
GLP-1 usage in the UK In 2023/24, over 64% of adults in England were estimated to be overweight or living with obesity (GOV.UK Obesity profile, May 2025), showing there is a clear market for weight loss drugs
Int J Environ Res Public Health 16(15):2720 Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan M, Camilleri LM (2008) The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study
6 A 68-week placebo-controlled trial of semaglutide (dosed at 2.4 mg SC weekly) for overweight/obese adults who did not have diabetes yielded a -15.3 kg weight loss (vs -2.6 kg with placebo)
Whether you are looking to improve muscle growth, enhance cognitive function, promote anti-aging, or boost immune health, our expert team is here to help you unlock your bodys full potential
We evaluate the complete spectrum of your health profile during the consultation, focusing on a personalized plan that aligns with your insurance, preferences, and health needs